Home > Documents in Process > Cross-Sectional FDG in Down Syndrome and Autosomal Dominant Alzheimer's Disease. > print

001     282588
005     20251209093037.0
024 7 _ |a 10.1002/ana.78002
|2 doi
024 7 _ |a pmid:40977577
|2 pmid
024 7 _ |a 0364-5134
|2 ISSN
024 7 _ |a 1531-8249
|2 ISSN
037 _ _ |a DZNE-2025-01348
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Abdelmoity, Omar
|0 0009-0003-8560-4339
|b 0
245 _ _ |a Cross-Sectional FDG in Down Syndrome and Autosomal Dominant Alzheimer's Disease.
260 _ _ |a Hoboken, NJ
|c 2025
|b Wiley-Blackwell
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1765268790_7325
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Directly compare the brain glucose patterns seen with [F-18] fluorodeoxyglucose (FDG) positron emission tomography (PET) between 2 genetically determined forms of Alzheimer's disease: Down syndrome (DS) and autosomal dominant Alzheimer's disease (ADAD).Cross-sectional analyses of FDG were performed in individuals with DS (n = 76) from the Alzheimer Biomarker Consortium-Down Syndrome (ABC-DS), ADAD (n = 297), and neurotypical familial controls (n = 188) from the Dominantly Inherited Alzheimer Network (DIAN). Within-group linear regression models and generalized additive models were performed for select regional FDG uptake measures (isthmus cingulate and inferior parietal, precuneus, middle temporal gyrus, and precentral gyrus). Age, sex, apolipoprotein (APOE) ε4 carrier status, and cortical amyloid burden were included within these analyses.Even 20 years before expected onset of clinical symptoms, FDG uptake was lower for DS compared to neurotypical familial controls (p < 0.01). ADAD baseline FDG was similar to neurotypical familial controls until 7 years before expected symptom onset. Both symptomatic individuals with DS and ADAD had lower FDG compared to neurotypical familial controls (p < 0.01). A higher amyloid burden was associated with lower FDG for both genetic forms, with similar rates of decline in FDG uptake for DS and ADAD who were amyloid positive.Brain glucose metabolism is substantially lower for people with DS, even in individuals who are cognitively stable. The patterns of FDG decline are distinct in these 2 genetically determined forms of AD. The diagnostic utility of FDG-PET is specific to the genetic form of AD. ANN NEUROL 2025;98:1237-1248.
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 0
536 _ _ |a 899 - ohne Topic (POF4-899)
|0 G:(DE-HGF)POF4-899
|c POF4-899
|f POF IV
|x 1
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a Fluorodeoxyglucose F18
|0 0Z5B2CJX4D
|2 NLM Chemicals
650 _ 7 |a Radiopharmaceuticals
|2 NLM Chemicals
650 _ 7 |a Glucose
|0 IY9XDZ35W2
|2 NLM Chemicals
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Alzheimer Disease: diagnostic imaging
|2 MeSH
650 _ 2 |a Alzheimer Disease: genetics
|2 MeSH
650 _ 2 |a Alzheimer Disease: metabolism
|2 MeSH
650 _ 2 |a Male
|2 MeSH
650 _ 2 |a Female
|2 MeSH
650 _ 2 |a Fluorodeoxyglucose F18: metabolism
|2 MeSH
650 _ 2 |a Cross-Sectional Studies
|2 MeSH
650 _ 2 |a Down Syndrome: diagnostic imaging
|2 MeSH
650 _ 2 |a Down Syndrome: metabolism
|2 MeSH
650 _ 2 |a Down Syndrome: genetics
|2 MeSH
650 _ 2 |a Positron-Emission Tomography
|2 MeSH
650 _ 2 |a Middle Aged
|2 MeSH
650 _ 2 |a Adult
|2 MeSH
650 _ 2 |a Aged
|2 MeSH
650 _ 2 |a Brain: diagnostic imaging
|2 MeSH
650 _ 2 |a Brain: metabolism
|2 MeSH
650 _ 2 |a Radiopharmaceuticals
|2 MeSH
650 _ 2 |a Glucose: metabolism
|2 MeSH
700 1 _ |a Wisch, Julie K
|0 0000-0003-3624-2784
|b 1
700 1 _ |a Kennedy, James T
|b 2
700 1 _ |a Goyal, Manu
|b 3
700 1 _ |a Vlassenko, Andrei
|b 4
700 1 _ |a Flores, Shaney
|b 5
700 1 _ |a Handen, Benjamin L
|b 6
700 1 _ |a Head, Elizabeth
|0 0000-0003-1115-6396
|b 7
700 1 _ |a Keator, David
|b 8
700 1 _ |a Rafii, Michael S
|b 9
700 1 _ |a Lao, Patrick
|0 0000-0003-2243-3547
|b 10
700 1 _ |a Lai, Florence
|b 11
700 1 _ |a Rosas, H Diana
|b 12
700 1 _ |a Hartley, Sigan L
|b 13
700 1 _ |a Zaman, Shahid
|b 14
700 1 _ |a Brickman, Adam M
|b 15
700 1 _ |a Tudorascu, Dana
|b 16
700 1 _ |a Lee, Joseph H
|b 17
700 1 _ |a Allegri, Ricardo Francisco
|b 18
700 1 _ |a Keefe, Sarah
|0 0000-0002-5943-0940
|b 19
700 1 _ |a la Fougère, Christian
|0 P:(DE-2719)9000177
|b 20
700 1 _ |a Llibre-Guerra, Jorge
|b 21
700 1 _ |a Ikeuchi, Takeshi
|b 22
700 1 _ |a Morris, John C
|b 23
700 1 _ |a Roh, Jee Hoon
|0 0000-0002-3243-0529
|b 24
700 1 _ |a Day, Gregory S
|0 0000-0001-5133-5538
|b 25
700 1 _ |a Levin, Johannes
|0 P:(DE-2719)2811659
|b 26
|u dzne
700 1 _ |a Schofield, Peter R
|b 27
700 1 _ |a Gordon, Brian A
|0 0000-0003-2109-2955
|b 28
700 1 _ |a Benzinger, Tammie L S
|b 29
700 1 _ |a Ances, Beau M
|b 30
700 1 _ |a Syndrome, Alzheimer's Biomarker Consortium-Down
|b 31
700 1 _ |a Network, the Dominantly Inherited Alzheimer
|b 32
|e Collaboration Author
773 _ _ |a 10.1002/ana.78002
|g Vol. 98, no. 6, p. 1237 - 1248
|0 PERI:(DE-600)2037912-2
|n 6
|p 1237 - 1248
|t Annals of neurology
|v 98
|y 2025
|x 0364-5134
856 4 _ |u https://pub.dzne.de/record/282588/files/DZNE-2025-01348_Restricted.pdf
856 4 _ |u https://pub.dzne.de/record/282588/files/DZNE-2025-01348_Restricted.pdf?subformat=pdfa
|x pdfa
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 20
|6 P:(DE-2719)9000177
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 26
|6 P:(DE-2719)2811659
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
913 1 _ |a DE-HGF
|b Programmungebundene Forschung
|l ohne Programm
|1 G:(DE-HGF)POF4-890
|0 G:(DE-HGF)POF4-899
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-800
|4 G:(DE-HGF)POF
|v ohne Topic
|x 1
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
|d 2024-12-18
|w ger
915 _ _ |a DEAL Wiley
|0 StatID:(DE-HGF)3001
|2 StatID
|d 2024-12-18
|w ger
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b ANN NEUROL : 2022
|d 2024-12-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2024-12-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2024-12-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2024-12-18
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2024-12-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2024-12-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2024-12-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2024-12-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2024-12-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2024-12-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2024-12-18
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2024-12-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2024-12-18
915 _ _ |a IF >= 10
|0 StatID:(DE-HGF)9910
|2 StatID
|b ANN NEUROL : 2022
|d 2024-12-18
920 1 _ |0 I:(DE-2719)1111016
|k AG Levin
|l Clinical Neurodegeneration
|x 0
920 1 _ |0 I:(DE-2719)1111015
|k Clinical Research (Munich)
|l Clinical Research (Munich)
|x 1
920 1 _ |0 I:(DE-2719)6000018
|k Tübingen common
|l Tübingen common
|x 2
980 _ _ |a journal
980 _ _ |a EDITORS
980 _ _ |a VDBINPRINT
980 _ _ |a I:(DE-2719)1111016
980 _ _ |a I:(DE-2719)1111015
980 _ _ |a I:(DE-2719)6000018
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21